Tempus
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
In Brief This Week: Tempus AI, Myriad Genetics, 23andMe, DNAnexus, Dovetail Genomics
News items for the week of Feb. 3, 2025.
Imagene, Tempus AI to Collaborate on AI-Based Lung Cancer Diagnostics
Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.
TD Cowen Reinstates Buy Rating for Tempus AI, Raises Price Target to $74
The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.
GenomeWeb Top 40 Rises 10 Percent in January, Outpacing Gains in Broader Market
The Dow Jones Industrial Average rose 5 percent while the Nasdaq rose 2 percent, and the Nasdaq Biotech Index rose 5 percent.